INTRODUCTION: Anti-tumor necrosis factor (anti-TNF) agents are commonly used in treatment of axial spondyloarthritis (axSpA), but clinical and radiological improvement is not achieved in all patients. We aimed to investigate the impact of anti-TNFs on inflammatory and noninflammatory parameters in patients with axSpA. METHODS: In this longitudinal study, 30 biologic naïve axSpA patients with high disease activity and 30 healthy controls were enrolled. All patients were treated with anti-TNF agents for 6 months. ASDAS-CRP, BASDAI, BASFI, BASMI, patient and physician global assessments were evaluated. C-reactive protein, COX2, TNF-α IL-6, IL-17, IL-22, IL-23, IL-33, sclerostin, dickkopf-1, and noggin levels were evaluated at baseline and at 6 months of anti-TNF treatment. RESULTS: At baseline, axSpA patients had significantly higher median (IQR) TNF-α levels, 34.4 (31.4-37.03) vs. 18.1 (12.1-28.4) pg/ml (p < 0.001), and lower DKK1, 446.7 (356.9-529.3) vs. 1088.7 (951.7-1244.4) pg/ml, and sclerostin, 312.4 (140.8-412.7) vs. 412.3 (295.4-512.8) pg/ml, compared to healthy controls (all p < 0.001). The median (IQR) serum levels of IL-17, IL-22, and IL-33 increased significantly after 6 months of anti-TNF treatment, from 93.3 (85.1-104.8) to 102.1 (86.6-114.6) pg/ml (p = 0.026), 159.2 (151.9-178.4) to 183.5 (156.3-304.6) pg/ml (p = 0.033), and 127.8 (106.6-186.1) to 147.06 (128.5-213.4) pg/ml (p = 0.016), respectively. Sclerostin and DKK-1 levels increased significantly after anti-TNF treatment from 312.4 (140.8-412.7) to 405.1 (276.3-452.5) pg/ml (p = 0.018) and 446.7 (356.9-529.3) to 881.3 (663.1-972.2) pg/ml (p < 0.001), while there was no significant change in noggin level. CONCLUSIONS: Many inflammatory cytokines increase after anti-TNF treatment and noggin is not affected by anti-TNF treatment in AxSpA. Noggin might be a therapeutic target in patients with axSpA. KEY POINTS: • Anti-TNF therapy is not sufficient for complete blockage of the inflammatory process in axial spondyloarthritis. • The increase in IL-17, IL-22, and IL-33 may decrease the efficiency of anti-TNF therapy. • Noggin might be a therapeutic target as a complementary or alternative approach to anti-TNF therapy in axial spondyloarthritis.
INTRODUCTION: Anti-tumor necrosis factor (anti-TNF) agents are commonly used in treatment of axial spondyloarthritis (axSpA), but clinical and radiological improvement is not achieved in all patients. We aimed to investigate the impact of anti-TNFs on inflammatory and noninflammatory parameters in patients with axSpA. METHODS: In this longitudinal study, 30 biologic naïve axSpA patients with high disease activity and 30 healthy controls were enrolled. All patients were treated with anti-TNF agents for 6 months. ASDAS-CRP, BASDAI, BASFI, BASMI, patient and physician global assessments were evaluated. C-reactive protein, COX2, TNF-α IL-6, IL-17, IL-22, IL-23, IL-33, sclerostin, dickkopf-1, and noggin levels were evaluated at baseline and at 6 months of anti-TNF treatment. RESULTS: At baseline, axSpA patients had significantly higher median (IQR) TNF-α levels, 34.4 (31.4-37.03) vs. 18.1 (12.1-28.4) pg/ml (p < 0.001), and lower DKK1, 446.7 (356.9-529.3) vs. 1088.7 (951.7-1244.4) pg/ml, and sclerostin, 312.4 (140.8-412.7) vs. 412.3 (295.4-512.8) pg/ml, compared to healthy controls (all p < 0.001). The median (IQR) serum levels of IL-17, IL-22, and IL-33 increased significantly after 6 months of anti-TNF treatment, from 93.3 (85.1-104.8) to 102.1 (86.6-114.6) pg/ml (p = 0.026), 159.2 (151.9-178.4) to 183.5 (156.3-304.6) pg/ml (p = 0.033), and 127.8 (106.6-186.1) to 147.06 (128.5-213.4) pg/ml (p = 0.016), respectively. Sclerostin and DKK-1 levels increased significantly after anti-TNF treatment from 312.4 (140.8-412.7) to 405.1 (276.3-452.5) pg/ml (p = 0.018) and 446.7 (356.9-529.3) to 881.3 (663.1-972.2) pg/ml (p < 0.001), while there was no significant change in noggin level. CONCLUSIONS: Many inflammatory cytokines increase after anti-TNF treatment and noggin is not affected by anti-TNF treatment in AxSpA. Noggin might be a therapeutic target in patients with axSpA. KEY POINTS: • Anti-TNF therapy is not sufficient for complete blockage of the inflammatory process in axial spondyloarthritis. • The increase in IL-17, IL-22, and IL-33 may decrease the efficiency of anti-TNF therapy. • Noggin might be a therapeutic target as a complementary or alternative approach to anti-TNF therapy in axial spondyloarthritis.
Authors: Désirée van der Heijde; Sofia Ramiro; Robert Landewé; Xenofon Baraliakos; Filip Van den Bosch; Alexandre Sepriano; Andrea Regel; Adrian Ciurea; Hanne Dagfinrud; Maxime Dougados; Floris van Gaalen; Pál Géher; Irene van der Horst-Bruinsma; Robert D Inman; Merryn Jongkees; Uta Kiltz; Tore K Kvien; Pedro M Machado; Helena Marzo-Ortega; Anna Molto; Victoria Navarro-Compàn; Salih Ozgocmen; Fernando M Pimentel-Santos; John Reveille; Martin Rudwaleit; Jochen Sieper; Percival Sampaio-Barros; Dieter Wiek; Jürgen Braun Journal: Ann Rheum Dis Date: 2017-01-13 Impact factor: 19.103
Authors: Désirée van der Heijde; Alan Kivitz; Michael H Schiff; Joachim Sieper; Ben A C Dijkmans; Jürgen Braun; Maxime Dougados; John D Reveille; Robert L Wong; Hartmut Kupper; John C Davis Journal: Arthritis Rheum Date: 2006-07
Authors: Michael M Ward; Atul Deodhar; Elie A Akl; Andrew Lui; Joerg Ermann; Lianne S Gensler; Judith A Smith; David Borenstein; Jayme Hiratzka; Pamela F Weiss; Robert D Inman; Vikas Majithia; Nigil Haroon; Walter P Maksymowych; Janet Joyce; Bruce M Clark; Robert A Colbert; Mark P Figgie; David S Hallegua; Pamela E Prete; James T Rosenbaum; Judith A Stebulis; Filip van den Bosch; David T Y Yu; Amy S Miller; John D Reveille; Liron Caplan Journal: Arthritis Rheumatol Date: 2015-09-24 Impact factor: 10.995
Authors: J Braun; J Brandt; J Listing; A Zink; R Alten; W Golder; E Gromnica-Ihle; H Kellner; A Krause; M Schneider; H Sörensen; H Zeidler; W Thriene; J Sieper Journal: Lancet Date: 2002-04-06 Impact factor: 79.321
Authors: Mandy J McGeachy; Yi Chen; Cristina M Tato; Arian Laurence; Barbara Joyce-Shaikh; Wendy M Blumenschein; Terrill K McClanahan; John J O'Shea; Daniel J Cua Journal: Nat Immunol Date: 2009-02-01 Impact factor: 25.606
Authors: Jonathan P Sherlock; Barbara Joyce-Shaikh; Scott P Turner; Cheng-Chi Chao; Manjiri Sathe; Jeff Grein; Daniel M Gorman; Edward P Bowman; Terrill K McClanahan; Jennifer H Yearley; Gérard Eberl; Christopher D Buckley; Robert A Kastelein; Robert H Pierce; Drake M Laface; Daniel J Cua Journal: Nat Med Date: 2012-07-01 Impact factor: 53.440
Authors: Robert D Inman; Xenofon Baraliakos; Kay-Geert A Hermann; Jürgen Braun; Atul Deodhar; Désirée van der Heijde; Stephen Xu; Benjamin Hsu Journal: Arthritis Res Ther Date: 2016-12-28 Impact factor: 5.156